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ABSTRACT
Introduction: The prevalence of paediatric obesity is
increasing, and with it, lifestyle-related diseases in
children and adolescents. High-intensity interval
training (HIIT) has recently been explored as an
alternate to traditional moderate-intensity continuous
training (MICT) in adults with chronic disease and has
been shown to induce a rapid reversal of subclinical
disease markers in obese children and adolescents.
The primary aim of this study is to compare the effects
of HIIT with MICT on myocardial function in obese
children and adolescents.
Methods and analysis: Multicentre randomised
controlled trial of 100 obese children and adolescents
in the cities of Trondheim (Norway) and Brisbane
(Australia). The trial will examine the efficacy of HIIT
to improve cardiometabolic outcomes in obese
children and adolescents. Participants will be
randomised to (1) HIIT and nutrition advice, (2) MICT
and nutrition advice or (3) nutrition advice.
Participants will partake in supervised exercise
training and/or nutrition sessions for 3 months.
Measurements for study end points will occur at
baseline, 3 months (postintervention) and 12 months
(follow-up). The primary end point is myocardial
function (peak systolic tissue velocity). Secondary end
points include vascular function (flow-mediated
dilation assessment), quantity of visceral and
subcutaneous adipose tissue, myocardial structure
and function, body composition, cardiorespiratory
fitness, autonomic function, blood biochemistry,
physical activity and nutrition. Lean, healthy children
and adolescents will complete measurements for all
study end points at one time point for comparative
cross-sectional analyses.
Ethics and dissemination: This randomised
controlled trial will generate substantial information
regarding the effects of exercise intensity on
paediatric obesity, specifically the cardiometabolic
health of this at-risk population. It is expected that
communication of results will allow for the
development of more effective evidence-based
exercise prescription guidelines in this population
while investigating the benefits of HIIT on subclinical
markers of disease.
Trial registration number: NCT01991106.
Strengths and limitations of this study
▪ To the best of our knowledge, this multicentre
trial is the first to use a combined exercise and
nutrition programme to examine the effect on
myocardial function in obese children and ado-
lescents. It is also one of few trials to explore
the efficacy and feasibility of high-intensity inter-
val training in this population.
▪ Strengths of this multicentre trial lie in the rigour
of the 12-week exercise and nutrition interven-
tion. The majority of exercise sessions will be
supervised to ensure that the correct exercise
intensity is achieved at all times.
▪ Extensive resting and exercise outcome mea-
sures will be performed at both trial centres.
Several measures are sensitive to small but
important longitudinal changes and are novel in
paediatric obesity.
▪ Like any paediatric longitudinal trial, challenges
remain around growth and maturation over the
trial period, which have the potential to confound
study end points. While the primary study end
point is related to cardiac growth, any changes
in cardiac size over the 1-year programme will
be accounted for using normalisation methods.
▪ Maturational changes will also be accounted for
through Tanner stages of puberty; however,
these may be subject to self-report error.
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INTRODUCTION
Paediatric obesity rates have increased over the last two
decades and is now prevalent in 3–15% of the paediatric
population according to the International Obesity Task
Force deﬁnition of obesity.1 More than 50% of obese
children will become obese adults2 with a signiﬁcantly
increased risk of developing non-communicable dis-
eases, including cardiovascular diseases, cancer and type
2 diabetes mellitus (T2DM).3 In 2012, these diseases
accounted for 63% of deaths worldwide3 and 77% of
disease burden in Europe.4 Indeed, a childhood and
adolescent body mass index (BMI) above the 95th
centile is a strong predictor of adult mortality rates.5
Furthermore, children and adolescents who had a base-
line BMI between the 85th and 95th centiles, deﬁned as
overweight, had a 30% increase in all-cause mortality.
This increased risk of death was independent of their
adult BMI.5
Obese children and adolescents may show abnormal
myocardial function when assessed through resting and
stress echocardiography.6–10 Echocardiographic techni-
ques such as tissue Doppler imaging are able to detect
subclinical heart disease.11 Previous investigations have
shown signiﬁcantly reduced tissue Doppler velocities in
obese youth compared with lean, healthy age-matched
control participants.12 In particular, peak systolic tissue
Doppler velocity (S′) closely reﬂects left ventricular con-
tractility,13 which can be improved with short-term exer-
cise training.14
Increased BMI or overweight in early life (1–9 years) is
associated with coronary artery disease15 and it is
acknowledged that atherosclerotic processes begin in
childhood.16 Impaired vascular function determined by
ﬂow-mediated dilation (FMD) of the brachial artery has
been observed in a number of obese paediatric
studies.17–22 Visceral adipose tissue is increased in
obesity which results in a greater release of bioactive
mediators.23 These inﬂuence the function of adipose
tissue and contribute to chronic disease, having a sub-
stantial impact on insulin sensitivity, inﬂammation and
subsequent risk for dyslipidaemia, T2DM and
atherosclerosis.24
Current paediatric guidelines for treating paediatric
obesity recommend lifestyle modiﬁcation to encourage
family-based behaviour change leading to a reduction in
energy intake and increase in physical activity.25 26 The
current treatment of paediatric obesity appears to have a
low success rate, most likely due to the heterogeneous
causes of obesity. Several recent meta-analyses and
reviews have demonstrated that the effectiveness of
paediatric obesity treatment is limited.27–29 The response
to treatment differs substantially between clinical centres
and treatment success appears to be age related. A large
European registry study showed signiﬁcant treatment
effects following a variety of lifestyle interventions,
including exercise programmes, nutrition education,
psychological intervention and parental education, in
<10% of participants over 2 years of follow-up.30
Furthermore, the treatment was least effective in partici-
pants older than 12 years. However, the low success rate
was in part accounted for by a high dropout rate. Two
recent reviews suggest that lifestyle and exercise inter-
ventions in obese children and adolescents can lead to
improvements in anthropometric and cardiometabolic
outcomes. These reviews are not inclusive of several
important outcomes such as myocardial and vascular
function, visceral adipose tissue or cardiorespiratory
ﬁtness.27 31 Myocardial and vascular function outcomes
have prognostic signiﬁcance,32 33 are able to identify sub-
clinical disease7 34 35 and may be improved with exercise
training.12 36 There is growing evidence that paediatric
obesity is associated with subclinical structural and func-
tional cardiovascular alterations.12 35 Myocardial dysfunc-
tion is more easily unmasked during stress as it precedes
resting abnormalities.12 37 Furthermore, low cardiorespira-
tory ﬁtness has shown independent associations with all-
cause mortality38 and improvements in cardiorespiratory
ﬁtness may attenuate risk of metabolic disease39 inde-
pendent of visceral adipose tissue.40 There is minimal
evidence regarding the effect of exercise intensity on
these novel markers in paediatric obesity.
Current worldwide data show that <50% of children
and adolescents accumulate the minimum recom-
mended 60 min of moderate-to-vigorous-intensity phys-
ical activity every day.41–46 Moreover, obese children
spend approximately 100 min a day being less physically
active than healthy weight or overweight children.47 The
promotion of high-intensity exercise in this obese paedi-
atric group may be an alternative to improve cardiometa-
bolic outcomes. High-intensity interval training (HIIT)
has recently been explored as an alternate exercise to
moderate-intensity continuous training (MICT) in
healthy adults as well as those with chronic disease. HIIT
involves a short bout of exercise at a high intensity, inter-
spersed by recovery periods in preparation for the next
bout. HIIT has resulted in improved health markers in
adults with cardiometabolic disease48 while demonstrat-
ing time efﬁciency.49 Four studies to date have examined
the physiological effects of HIIT in obese children and
adolescents and reported positive ﬁndings.12 50–52
Children and adolescents expressed increased enjoy-
ment during HIIT49 and the stop–start nature of HIIT
may reﬂect play-based activities traditionally observed
during childhood. This is particularly important as
enjoyment is a strong determinant of exercise adher-
ence.53 54 In fact, a ‘lack of enjoyment’ is frequently
reported as a barrier by obese children.55 While the
chosen HIIT protocol (40 min; 10 min warm-up,
4×4 min intervals interspersed by 3 min active recovery,
5 min cool down) has a similar time commitment to the
MICT protocol (44 min), this is a result of equalising
energy expenditure between training types.56 We have
previously shown that this particular HIIT protocol in
obese adolescents can almost normalise cardiac function
to that observed in lean counterparts, and high compli-
ance to the HIIT protocol was noted.12 However, the
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pilot trial had a small sample size and did not include
comparative treatments.12 The 4×4 HIIT protocol has
shown great efﬁcacy in clinical adult populations, includ-
ing patients with heart failure, coronary artery disease,
hypertension, obesity and the metabolic syndrome.48
Weston et al48 recommend the use of this protocol due
to greater time efﬁciency , that is, increases in cardio-
respiratory ﬁtness following a HIIT programme were
nearly double the increases seen after a MICT pro-
gramme (19.4% vs 10.3%). In the studies reviewed,
Weston et al48 found that HIIT was able to elicit many
superior beneﬁts to MICT, albeit in only a slightly
shorter time period. This randomised controlled trial
aims to examine the physiological efﬁcacy of HIIT com-
pared with MICT in a multicentre randomised con-
trolled trial, thereby improving the current literature
and informing the treatment options for paediatric
obesity.
OBJECTIVES
The primary aim of this randomised controlled trial is to
compare the effectiveness of three 12-month interven-
tions: HIIT and nutrition advice, MICT and nutrition
advice or nutrition advice alone on myocardial function
in obese children and adolescents. It is hypothesised
that HIIT will be superior in improving myocardial func-
tion compared with MICT. Secondary outcome measures
will include vascular function, body composition (total,
visceral and subcutaneous adipose tissue depots and
lean muscle mass), cardiac structure, cardiorespiratory
ﬁtness, autonomic function, serum fasting lipids and
insulin sensitivity, biomarkers of inﬂammation, satiety
and oxidative stress markers, physical activity levels and
nutrition. Phase I of the trial will examine the effective-
ness of an intensive 3-month period on the stated out-
comes with assessments at baseline and after 3 months
of supervised training. Phase II of the trial aims to deter-
mine the amount of supervision required to maintain
exercise habits over a 9-month home-based training
period. For this phase, participants will be rerandomised
to (1) monthly supervised exercise or (2) home-based
exercise only. Final assessments will be completed at
12 months. Lastly, the trial aims to determine whether
any of the intervention arms are able to improve and
normalise outcomes comparable with those found in
healthy weight children and adolescents. It is for this
comparative purpose that an age-matched, lean and
healthy control group of children and adolescents will
be assessed at a single time point.
METHODS AND ANALYSIS
Study setting
This is a multicentre randomised controlled intervention
trial. The study centre is located at the Norwegian
University of Science and Technology (NTNU),
Trondheim, Norway. The other centre is at the
University of Queensland (UQ), Brisbane, Australia.
Testing and training will take place in the university
research laboratories at these institutions and hospital
outpatient settings (St. Olav’s Hospital in Trondheim
and the Wesley Hospital in Brisbane).
Participants and eligibility criteria
The study cohort will include 100 obese and 100 lean,
healthy control children or adolescents aged between 7
and 16 years old. Obesity in this population will be deﬁned
as a BMI equal to or greater than the 95th centile (age
and sex speciﬁc).57 Study exclusion criteria include hyper-
tension (deﬁned as blood pressure above the 95th centile
for systolic or diastolic values), any history or evidence of
heart disease and/or an abnormal resting or stress echo-
cardiography which indicates it would be unsafe to partici-
pate, any chronic disease, for example, chronic asthma,
kidney disease, diabetes, current smoking habits or an
orthopaedic/neurological disorder that may limit ability
to exercise, diagnosed attention deﬁcit hypersensitivity dis-
order and use of steroid medications. Conditions not spe-
ciﬁcally aforementioned may serve as criteria for exclusion
at discretion of the clinical site. Furthermore if medical
conditions become apparent in participants during assess-
ments or exercise training, medical advice will be sought
and the intervention may be discontinued in the individ-
ual. Lean healthy control participants must have an age
and sex-speciﬁc BMI in the healthy range (5th–85th
centile) to be included.57 Study exclusion criteria are iden-
tical in lean healthy control participants. The lean healthy
control participants will not partake in an intervention but
will be assessed for cross-sectional comparative analyses.
Interventions
A randomised block design will be used. Obese partici-
pants will be randomised to one of three groups and will
be stratiﬁed according to age and sex. Lean participants
will be stratiﬁed to the same groups but no intervention
will be administered (ﬁgure 1).
Exercise protocol
The exercise intervention involves a combination of
supervised and unsupervised exercise training sessions.
Participants will attend at least two, up to three, super-
vised training sessions each week for 12 weeks. If partici-
pants choose to attend two supervised sessions, they will
be required to complete a third unsupervised exercise
session at home. Following the 3-month supervised
period, participants in each of the two exercise groups
will be randomised to ‘monthly supervised exercise’ or
‘home-based exercise only’ from 3 to 12 months. During
this time, participants in the HIIT and MICT groups will
be asked to complete three unsupervised training ses-
sions each week for 9 months and the ‘monthly super-
vised exercise’ group will be asked to attend once
monthly supervised training sessions at the clinical site.
Supervised exercise training (HIIT and MICT) will
consist of walking or running on a treadmill or cycling
on a stationary bike based on participant preference.
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During the unsupervised exercise session, the mode can
vary. Necessary adjustments to speed/grade and resist-
ance will be made over the course of the intervention to
ensure that target heart rate zones are achieved at all
times. Heart rate, rating of perceived exertion (RPE)
(Pictorial Children’s Effort Rating Table—PCERT) and
exercise mode will be recorded in a training booklet
during supervised and unsupervised exercise sessions. In
the event of limited access to a heart rate monitor
during unsupervised sessions, participants will be asked
to replicate the supervised session as closely as possible
(ie, identical treadmill speed/grade for intervals and
active recovery periods) and to aim for similar RPE
recordings as in the supervised sessions. Participants
who wish to complete an unsupervised session each
week will be provided with a separate booklet, which will
be kept alongside the clinic version. Each participant
will also receive a training booklet for the follow-up
period allowing them to record details of each session
completed.
High-intensity interval training
Participants randomised to HIIT will perform a 10 min
warm-up at 60–70% of maximal heart rate (HRmax).
Following this, they will walk, run or cycle at 85–95% of
their HRmax for four, 4 min intervals, with 3 min of
active recovery (50–70% of HRmax) between the inter-
vals. Participants will perform a 5 min cool down period
at the end amounting to a total exercise time of 40 min.
Moderate-intensity continuous training
Participants randomised to the MICT group will walk,
run or cycle continuously at 60–70% HRmax for 44 min
to approximate the average energy expended by the
HIIT group as previously calculated by our research
group.56
Nutrition advice
HIIT, MICT and nutrition groups will receive 8 to 10,
20 min individual nutrition sessions with a dietitian over
the 12-month period. Content of the sessions will
include healthy food choices, portion sizes and regular
meal times. The nutritional advice given will reﬂect
current Norwegian and Australian eating guidelines and
will be location speciﬁc.58 59 The nutrition group will
not be provided with any prescribed supervised exercise.
Outcomes
Measurements will take place at baseline, 3 months (end
of the supervised exercise intervention period) and at
12-month follow-up.
Participant preparation guidelines
Participants will be informed of preparation require-
ments, which will be checked prior to the assessments.
Stress echocardiography and cardiorespiratory fitness
testing
Assessment of myocardial function and structure and
maximal oxygen uptake (VO2max) will require partici-
pants to refrain from eating heavy meals up to 2 h
before the testing session and avoid any foods contain-
ing caffeine for this time period.
Vascular function, body composition and blood collection
Assessment of vascular function and body composition
(BodPod), and blood collection will be completed in a
fasted state (8–12 h) and participants will be instructed
to avoid caffeine, vitamin C, alcohol, drugs, stimulants
Figure 1 Intervention groups/stratification.
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and medications for this time period. Additionally, parti-
cipants must refrain from intense exercise for 48 h prior
to testing. To avoid dehydration, participants will be
instructed to drink at least 0.5 L of water before attend-
ing the assessment.
Myocardial function (rest and stress echocardiography)
Primary outcome measure: S′ at rest (left ventricle).
Secondary outcome measures: S′ (during exercise, both
ventricles), S′ (rest, right ventricle), peak diastolic tissue
velocities (both ventricles), tricuspid annular plane sys-
tolic excursion (TAPSE), global strain and strain rate,
aortic ﬂow and cardiac dimensions.
A full resting echocardiogram will be performed with a
Vivid 7/E9 ultrasound machine (GE Vingmed
Ultrasound, Horten, Norway) using a phased array trans-
ducer (GE M3S). Three cine loops from the three stand-
ard apical planes (four chamber, two chamber and
long axis) and the right ventricle will be recorded in
grey-scale harmonic mode and tissue Doppler mode sim-
ultaneously. Left ventricular (LV) standard Doppler
echocardiographic indices will be measured and body
surface area (m2) will be used to normalise cardiac
dimensions for differences in body size. Mitral annulus
excursion, pulsed wave tissue Doppler velocities, peak sys-
tolic (S′), peak early diastolic (e′) and peak late diastolic
(a′) will be measured at the atrioventricular (AV) plane
level in four-chamber and two-chamber view and a mean
of the four points will be used. Standard Doppler echo-
cardiographic indices of right ventricular function will be
measured as well as TAPSE, S′, e′, a′. Deformation
(strain) and deformation rate (strain rate) will also be
analysed by speckle tracking (2D strain) and tissue
Doppler imaging.
Following the resting echocardiogram, individuals will
exercise on a stationary cycle ergometer in an upright
position. The exercise protocol will start at an intensity
of 25 W with 25 W increments every 3 min until partici-
pants have attained their HRmax or are no longer able
to maintain a constant cadence. Recordings will be
made at baseline and peak assessing apical four
chamber and two chamber in B-mode and tissue
Doppler as well as mitral and aortic ﬂow. A three-lead
ECG, blood pressure and ratings of perceived exertion
(PCERT) will be monitored and recorded at the end of
each stage.
EchoPAC (GE Vingmed Ultrasound AS, Horten,
Norway) will be used for all echocardiographic analysis
by an investigator blinded to the group allocation of the
subjects.
Visceral, subcutaneous and total abdominal adipose tissue
(MRI)
At the Brisbane site, visceral, subcutaneous and total
abdominal adipose tissue will be measured using a 1.5 T
MRI system (Siemens Symphony Sonata, Siemens,
Erlangen, Germany) equipped with a six-channel body
matrix coil and a six-channel spine coil. Subjects will be
positioned supine inside the magnet and transversal
images will be acquired using true fast imaging steady
state precision (TRUFISP) technique with breath hold
(repetition time=3.76 ms; echo time=1.88 ms; ﬂip angle
75°; matrix=220×256; rectangular ﬁeld of view (FOV)
=400 mm×400 mm; slice thickness=8 mm; 14 slices;
acquisition time=12 s). We will acquire 14 axial slices,
8 mm thick centred over the umbilicus during breath
hold using a Dixon technique.
At the Trondheim site, visceral, subcutaneous and
total abdominal adipose tissue will be measured using a
3 T MRI system (Siemens Skyra; Siemens, Munich,
Germany) equipped with an 18-channel body coil and a
32-channel spine coil. Participants will be positioned
supine inside the magnet and transversal images will be
acquired using T1-weighted Dixon vibe sequences with
breath hold (repetition time=4.04 ms; echo time=1.3 ms
and 2.50 ms; ﬂip angle=9°; matrix=320×256; rectangular
FOV=380 mm×309; slice thickness=3 mm; 52 slices;
number of averages=1; band width=1120 Hz/pixel; gen-
eralised autocalibrating partially parallel acquisition
(GRAPPA) parallel imaging acceleration factor 2, acqui-
sition time=17 s). If the given FOV is too small to cover
the whole subject, the FOV is increased sufﬁciently
before scanning. The Dixon sequences will be acquired
twice to assure a set of successful images.
The MRI scans will be exported and anonymised.
Images will be converted to NIfTI format and analysed
using in-house software developed in MATLAB
(TheMathWorks, Inc, Natick, Massachusetts, USA). Five
consecutive slices at and above the L4/L5 vertebral disc,
with localising images used to conﬁrm the level, will be
selected for quantiﬁcation of visceral and subcutaneous
fat in each participant. Two regions of interest (ROIs)
will be manually drawn on the images by a trained radi-
ologist. One ROI will delineate the subcutaneous com-
partment and the second ROI will delineate the
intra-abdominal and retroperitoneal areas together to
quantify visceral adipose tissue. Visceral and subcutane-
ous adipose tissue will be summed to quantify total
adipose tissue. The area of the fat inside each ROI will
be calculated by counting the number of pixels with
intensities above a selected threshold and multiplied by
the pixel area. Slices will be manually adjusted for
threshold intensity in order to compensate for lack of
uniformity between slices. Values calculated from the
ﬁve slices will be averaged to provide a mean area
(cm2).
Vascular function (FMD)
Endothelial function of the brachial artery will be mea-
sured via FMD using high-resolution vascular ultrasound
(12–14 MHz ultrasound Doppler probe, Vivid 7 system/
Vivid I system; GE Vingmed Ultrasound AS, Horten,
Norway) according to current guidelines.60 Participants
will lie supine for 10 min in a quiet, dark environment
prior to the start of the procedure. A transducer will be
placed against the brachial artery and following image
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optimisation, baseline images will be recorded for at
least 30 s in live duplex mode (simultaneous B-mode
diameter and pulsed wave Doppler velocity signals). A
blood pressure cuff will then be placed distal to the
region of interest and inﬂated for 5 min at 200 mm Hg.
This will reduce blood ﬂow to the hand. Upon cuff
release, 10 beat cine loops will be recorded in duplex
mode (B-mode diameter and pulsed wave Doppler vel-
ocity signals) at 10, 30, 60, 90, 120, 150 and 180 s (UQ),
or continuously for 3 min (NTNU) to measure the
change in the diameter of the artery following increased
blood ﬂow and shear stress to the vascular wall. Data will
be assessed by custom-made automated edge-detection
software, which is independent of investigator bias.
Brachial artery diameter and shear rate will be quanti-
ﬁed from the ultrasound studies to assess FMD.
Cardiorespiratory fitness
VO2max will be measured during uphill treadmill
walking or running using expired air gas analysis
(Metamax3B, Cortex Biophysik, GmbH, Leipzig,
Germany or Jaeger Oxycon Pro, CareFusion, Hoechberg,
Germany). An incremental, ramp protocol will be used
for all participants. A 4 min warm-up at 4 km/h and 0%
grade will precede the test; however, the speed can be
modiﬁed to match the preferred walking speed of the
participant. A walking or running protocol is available
depending on participant preference and ﬁtness.
The walking protocol consists of 1 min stages where
speed is set at preferred walking speed and gradient is
increased by 2% each minute. If the participant reaches
a steep gradient (this will be adjusted by researchers
depending on age and height of participant: <12 years
approximately 12%, ≥12 years approximately 16%),
speed will be increased by 1 km/h each minute
thereafter.
The running protocol consists of 1 min stages where
gradient is set at approximately 10% (this will be
adjusted by investigators depending on age and height
of participant) and speed is increased by 1 km/h each
minute. If the participant reaches a speed that can no
longer be safely increased, gradient will be increased by
1% each minute thereafter.
A levelling off of oxygen uptake (VO2) despite
increased workload and respiratory exchange ratio
(RER) ≥1.05 will be used as criteria for VO2max.
A levelling off (plateau) in VO2 will be deﬁned
using 30 s epochs. If the VO2 increase is
(,150mLO2=min)=ðbodymassÞ with an increase in
workload, then a plateau is assumed. If the participant
has reached a plateau and the RER criterion has been
satisﬁed then the two highest consecutive 30 s values will
be averaged to obtain the VO2max value. If the partici-
pant has not reached a plateau, VO2peak is determined
by using the average of the two highest values attained.
It is highly likely that most participants will not reach a
VO2max, and therefore group values will be reported as
VO2peak.
Heart rate will be measured continuously during the
test (Polar, Polar Electro, Kempele, Finland) to deﬁne
HRmax.
Heart rate variability
Participants will lie supine for 10 min in a quiet, dark
environment prior to commencement of the procedure.
Participants will be asked to lie as still as possible for
5 min while an ECG trace is monitored and recorded
for calculation of heart rate variability. RR intervals
obtained from the ECG will be processed using Kubios
HRV (University of Eastern Finland, Finland).
Body composition
At the Brisbane site, dual energy X-ray absorptiometry
(DXA) will be used to determine body composition
(adipose tissue and lean muscle mass). This will require
the participant to lie motionless while an X-ray of their
entire body is taken using the DXA scanner (Hologic,
QDR Series, Massachusetts, USA). The duration of a
whole body scan is 7 min.
At the Trondheim site, a BodPod (COSMED, Rome,
Italy) will be used to determine body composition
(adipose tissue and lean muscle mass). Participants are
required to be fasted (8 h) and will be tested in minimal
clothing (underwear only). The procedure takes 15 min
in total with 5 min spent in the BodPod.
Blood biochemistry
Venous blood samples will be collected from a superﬁ-
cial antecubital vein according to standard phlebotomy
procedures. Samples will be collected into three vacutai-
ners containing EDTA, ﬂuoride oxalate and clot activa-
tors. Vacutainers will be stored on ice or left to clot at
room temperature for at least 30 min (serum samples).
Two aliquots of whole blood will be pipetted out and fol-
lowing this, samples will be centrifuged at 2500 rpm, 4°C
for 10 min. Plasma/serum will be aliquoted and stored
at −80°C for later analysis.
Samples will be analysed for lipids (total cholesterol,
low-density lipoprotein (LDL), high-density lipoprotein
(HDL), triglycerides), glucose and insulin (to establish
insulin resistance and β cell function using Homeostatic
Model Assessment of Insulin Resistance (HOMA-IR)) and
C reactive protein (CRP) using spectrophotometry (Cobas
Mira, Roche Diagnostics, Australia). Insulin resistance and
β cell function will be calculated using the HOMA model
(based on fasting glucose and insulin concentrations),
where ðHOMA  IR) ¼ ðglucose insulin=22:5Þ and
ðHOMA  bÞ ¼ ð20insulin=glucose 3:5Þ%. Satiety
hormones (ghrelin, leptin, peptide YY, obestatin), inﬂam-
matory markers (tumour necrosis factor α (TNFα), inter-
leukin 6 (IL-6), IL-10, plasminogen activator inhibitor 1
(PAI-1)), adiponectin and soluble intercellular adhesion
molecule 1 (si-CAM-1) will be measured using speciﬁc
ELISA kits (R&D systems, Inc, Minneapolis, Minnesota,
USA). Total nitrite concentration will be quantiﬁed using
a commercially available assay for nitric oxide (NO2
−)
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detection (R&D systems, Inc, Minneapolis, Minnesota,
USA). Oxidative stress and antioxidant status will be mea-
sured using the following methodologies. Total
F2-isoprostanes will be extracted and analysed using a
method developed by the Brisbane laboratory.61 The
laboratory coefﬁcient of variation for this assay is 4.5%.
Protein carbonyls will be analysed using adapted method-
ology from Levine et al.62 The laboratory coefﬁcient of
variation for this assay is 11.9%. Plasma glutathione per-
oxidase (GPx) activity will be measured spectrophotomet-
rically (Cobas Mira, Roche Diagnostics, Switzerland) via
the oxidation of NADPH to NADP by modifying
methods.63 64 The laboratory coefﬁcient of variation for
this assay is 2.4%.
Physical activity and nutrition measurements
Accelerometry will be used to measure physical activity
at baseline and at the 3-month assessment. Participants
will be asked to wear an accelerometer for 7 days
(Brisbane: ActiGraph, Florida, USA and Trondheim:
SenseWear, BodyMedia, Inc, Pittsburgh, Pennsylvania,
USA). To be included in the analysis, participants will be
required to have a minimum of 4 valid days, 1 of which
must be a weekend day. Participants in Brisbane will be
asked to wear the ActiGraph monitor during waking
hours, except for when sleeping or during water-based
activities. Participants will also be asked to keep a brief
log to record wake/sleep times and any time the
monitor was removed for >10 min (eg, sleep, shower,
etc). The ActiGraph accelerometer will be initialised to
sample at 30 Hz and data will be aggregated in 15 s
epochs. To be considered a valid day, there must be a
minimum of 10 h of wear time and non-wear time cri-
teria will be 60 min or more of consecutive zeros.
Accelerometer cut points previously validated in a paedi-
atric population65 will be used to determine average
time per day spent in light physical activity, moderate
physical activity and vigorous physical activity. ActiGraph
data will be analysed using ActiLife software (V.6).
Participants in Trondheim will be asked to wear the
SenseWear armband for 24 h each day. The device will
be removed during water-based activities. To be consid-
ered a valid day, at least 85% of a 24 h day must be
recorded and time spent in light physical activity
(1.6–2.9 metabolic equivalents (METS)), moderate phys-
ical activity (3–5.9 METS) and vigorous physical activity
(>6 METS) will be determined. SenseWear data will be
analysed using BodyMedia (V.8.1, Pittsburgh,
Pennsylvania, USA).
Participants will also complete a physical activity ques-
tionnaire designed by the Norwegian Directorate of
Health with content focusing on total physical activity,
physical activity at school and home and weekday/
weekend screen time.66
Food record booklets will be given to participants and
a 3–4-day record will be requested (must include 1
weekend day). Food records will be analysed using
either FoodWorks (Xyris Software, Australia) for the
Australian cohort or using the food database KBS AE-07
and KBS software system (KBS, V.4.9, 2008, Department
of Nutrition, University of Oslo, Norway) for participants
in Norway.
Other measures
Height, weight, waist circumference (WC) and hip cir-
cumference (HC) and blood pressure will be measured
using standard approaches.67
Participant timeline
Figure 2 illustrates the schedule for measurement of out-
comes and the intervention.
Sample size
The sample size was calculated for a one-way analysis of
variance (ANOVA) comparing the mean change in
resting S′ between the three groups from preinterven-
tion to postintervention. Although the data will be ana-
lysed using a linear mixed model (LMM), a simpliﬁed
calculation of sample size for a one-way ANOVA provides
a conservative estimate of the sample size required for
the LMM. Simulations run by our research group
support this assumption. For calculation of sample size,
the clinically meaningful difference in means was set to
1 cm/s, using the values 9.5, 10 and 10.5 cm/s for the
nutrition, MICT and HIIT groups, respectively. The SD,
assumed to be equal for all groups, was set to
SD=0.9 cm/s.12 To obtain a power of 0.80 for the overall
test of differences in means, using a signiﬁcance level of
Figure 2 A scheme illustrating a time schedule for enrolment, intervention and assessment of obese participants.
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0.05, 17 individuals are required in each group. A
further 40 individuals are required to account for the
four stratiﬁcation groups (ﬁgure 1) included in all statis-
tical analyses. To account for 15% dropout, a total of
105 individuals are required to enter the intervention.
In order for the lean control group to be closely
matched in age, sex and sample size, 105 lean partici-
pants are required for assessment at a single time point.
Recruitment
A variety of recruitment strategies will be employed at
each site to achieve adequate participant enrolment and
reach target sample size. At the Trondheim site, a
regular advertisement will be placed in the local news-
paper. In addition, advertisements will be published on
the university and hospital websites and ﬂyers will be dis-
tributed at strategic locations. Every 6 months, local
health nurses and medical centres will be informed
about the study. A website will be set up with a linked
preliminary screening tool and programme contact
form. A video blog about childhood obesity research will
be used for media outlets and publicity through newspa-
pers and television. Social media such as Facebook will
also be used. Similar strategies will be used at the
Brisbane site. An advertisement for the study will be
placed in the university staff newsletter and ﬂyers will be
placed around the campus. Schools in a 30 km radius
will be emailed with a newsletter advertisement. Health
and ﬁtness centres and medical centres within a 15 km
radius will be asked to advertise the programme on a
noticeboard. A website will be set up with a linked pre-
liminary screening tool and programme contact form.
Google AdWords will be employed as a continuous
recruitment pathway strategy with approximately 10–15
clicks resulting in website views expected each day. Local
dietitians and paediatricians will also be contacted for
referrals into the programme. Finally, media outlets will
be contacted for newspaper and television coverage.
Assignment of interventions
Allocation sequence generation
Computer-generated random numbers will be used for
allocation sequence generation with stratiﬁcation com-
pleted according to age and sex (see ﬁgure 1). The four
stratiﬁcation groups will be:
1. Females 7–10 years
2. Males 7–12 years
3. Females 10–16 years
4. Males 12–16 years
Allocation concealment will be implemented using
central randomisation through a web-based program
that will generate the allocation sequence. A study inves-
tigator at each centre will enter the details of eligible
obese participants and the web-based program will
provide the group allocation for the intervention. The
investigator will then inform the parent or guardian.
Lean and healthy control participants will also be regis-
tered and stratiﬁed using the web-based program.
Blinding
As this is an exercise intervention, trial participants
cannot be blinded to group assignment. However,
outcome assessors and data analysts will be blinded to
intervention assignment. Outcome assessors of the
primary outcome are independent of the clinical centre
and will not interact with participants outside of the
assessments. Participants will be asked not to divulge
their group allocation during testing visits. All data is
stored using participant ID number only and data ana-
lysis that is subject to investigator bias will occur without
knowledge of intervention assignment.
Data management and analysis
Data management
Double data entry will be administered at each site to
ensure data quality. Data will be stored in a reidentiﬁable
format (participant numbers only). A password-
protected sheet will enable the participants’ numbers be
linked to names when required.
During and after the research project, data on paper
will be kept in a locked ﬁling cabinet. Electronic data
will be stored on password-protected computers or exter-
nal hard drives with access granted only to members of
the research team. Tissue samples will be identiﬁed by
participant number only and will be stored in a secure
locked area.
Information collected will be disposed of 10 years after
study completion. Paper documents will be shredded
and disposed of, while electronic information will be
erased.
Statistical methods
An intention to treat analysis will be used. A per proto-
col analysis will also be conducted where completion of
80% of the 3-month intervention is required. Data will
be analysed with SPSS Statistics (IBM, New York, USA),
Stata (Texas, USA) and R (R Core Team, Vienna,
Austria). Normality of data will be checked using one
or more normality tests. Descriptive statistics will be
computed for variables of interest and continuous data
will be reported as means and SDs if data is normally
distributed. Non-continuous and non-normally distribu-
ted data will be reported as frequencies, medians and
IQRs.
Statistical analysis comparing between group differ-
ences (three groups) following the intervention will be
conducted using an LMM. This technique calculates
between-group and within-in group differences (from
baseline to postintervention) within the same model. An
LMM is also able to adjust for stratiﬁcation variables
(age, sex) and for a centre effect if present. Adjustment
for a centre effect is particularly important, as there are
minor discrepancies in the intervention and outcome
methodologies, as well as a large climatic difference due
to varying geographical locations of the clinical centres.
In order to examine the effect of supervision during the
9-month follow-up period (from 3 to 12 months), an
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LMM will be used again with supervision included as an
additional explanatory variable in the model.
To compare between-group differences in binary cat-
egorical data following the 3-month intervention, a gen-
eralised LMM (GLMM), which accounts for time
correlations, will be used.
Monitoring
Harms
If a participant develops a medical or surgical illness
during the study, the Data Monitoring Committee in
cooperation with the participant’s general practitioner
will ascertain continuing or resuming participation in
the intervention. In the event of a medical emergency
occurring at the clinical sites, the study staff will under-
take, under direction of the principal investigator or
designated staff, all necessary supportive medical care.
All adverse events (AEs) will be reported between the
ﬁrst trial-related study procedure and the last during
study intervention. Medical events that occur between
the signing of the informed consent form and the ﬁnal
study-related procedure will be documented in the
medical history.
Participants should voluntarily report any AEs or in
response to general, non-directed questioning (eg, ‘How
has your health been since the last visit?’). For each AE
volunteered by the participant, the investigator will
obtain all the information required to complete the AE
documentation. All AEs regardless of seriousness, sever-
ity or presumed relationship to the study will be
recorded using medical terminology in the source docu-
ment and on the case report form. Safety-related events
will be reported in a timely fashion as required by the
Data Monitoring Committee and the Ethics Committees
responsible for the study.
ETHICS AND DISSEMINATION
Consent and assent
Participants and their parents will provide informed
consent after the principal investigator has briefed them
on the study and answered questions. Two separate
informed consent sheets will be signed with content
adjusted to suit a paediatric population (participant and
parent/guardian signs one while the other is signed by
the participant only).
Confidentiality
Information collected directly from participants will be
in a reidentiﬁable form and any information collected
for, used in or generated by this project will not be used
for any other purpose. The site principal investigator
and associated research personnel such as the study
dietitian will have access to information.
Dissemination policy
Results of this clinical trial aim to be disseminated
through peer-reviewed journal articles, conference
abstracts and presentations, as well as media publica-
tions. It is hoped that results of the clinical trial will
inform future paediatric obesity management strategies.
Patient and public involvement
Patient and public involvement (PPI) strategies were
implemented following the conclusion of preceding
pilot trial. Several organisations were involved in the
conception of protocol design in Brisbane (Child
Obesity Program at the Mater Children’s Hospital/Lady
Cilento Children’s Hospital and The Children’s
Nutrition Research) and Norway (Centre for Obese
Adults and Children at St. Olav’s Hospital, the Cardiac
Exercise Research Group at NTNU, the Norwegian
Physiotherapist Association, as well as local schools and
physical education (PE) teachers in Trondheim). Six
clinicians were also actively involved during the protocol
development phase, including cardiologists, paediatric
endocrinologists and dietitians. The conclusion of the
pilot trial provided an opportunity to receive feedback
from the patient population in question. While a propor-
tion of obese adolescents disliked HIIT until they
improved their cardiorespiratory ﬁtness, the majority
reported enjoyment, which resulted in high training
attendance and compliance. Freedom with exercise
modality also increased HIIT feasibility in this group. A
similar protocol was therefore implemented in the
current intervention.
During the ongoing clinical trial, feedback from partici-
pants and families has been welcomed and resulted in
minor protocol adjustments. Notable adjustments include
the structure of assessments and frequency of supervised
exercise sessions offered in order to aid adherence.
DISCUSSION
Reduced physical activity and poor nutrition are the
main causes of obesity in children and adolescents. A
large proportion of the paediatric population does not
meet exercise guidelines, and energy intake in obese
children is often larger than in healthy weight chil-
dren.68 69 Consequently, paediatric obesity has increased
steadily in several countries over the last 30 years.70–72
Current worldwide data suggest that only 5–50% of chil-
dren and adolescents are meeting current exercise
guidelines.41–46 73 Furthermore, obese children are less
physically active compared with healthy weight chil-
dren74 75 and spend more time in sedentary activ-
ities.76 77 Low levels of leisure time physical activity are
associated with an increased risk of cardiovascular and
metabolic diseases.78 Therefore, encouraging all chil-
dren to increase their levels of physical activity and
reduce their sitting time could help to avoid excess
weight gain and associated health risks.79 We therefore
are striving to investigate a time-efﬁcient form of exer-
cise, which could potentially induce physiological
changes and reduce cardiovascular risk factors in obese
children and adolescents. The importance of nutrition
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in this population stipulated that the exercise interven-
tions were combined with nutrition advice and com-
pared with a nutrition advice only group as well.
This clinical trial involves the largest known cohort of
obese children and adolescents in a HIIT intervention to
date. Valuable information about the effects of exercise
intensity on cardiac and vascular structure and function,
body composition, cardiorespiratory ﬁtness, biochemistry
markers, physical activity, nutrition and quality of life in
obese children and adolescents will be gathered.
Importantly, this trial will contribute to the currently
small, but important, body of evidence exploring cardiac
function during exercise. While resting function may
remain normal in paediatric obesity, stress echocardiog-
raphy may unmask subclinical cardiac disease35 and lead
to better patient management and outcomes.
Dissemination of the knowledge gained from this trial
is expected to inform physical activity and exercise
guidelines for this speciﬁc population in an attempt to
dampen the impact that obesity has on physiological
systems as well as reduce risk factors for future develop-
ment of comorbidities such as T2DM and heart disease.
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